{
    "clinical_study": {
        "@rank": "156355", 
        "arm_group": {
            "arm_group_label": "Patients implanted with an Argus II Retinal Prosthesis"
        }, 
        "brief_summary": {
            "textblock": "This post-approval study is being implemented to monitor the use of Argus II System in a\n      larger US population than available within pre-approval studies.  An attempt will be made to\n      include all eligible and willing subjects implanted with Argus II System in the United\n      States.\n\n      Safety data will be monitored to ensure continued acceptability of risks to study subjects.\n      The utility (i.e. visual function and functional vision) and reliability of Argus II System\n      will also be evaluated.\n\n      There is no study hypothesis."
        }, 
        "brief_title": "New Enrollment Post-Approval Study of the Argus\u00ae II Retinal Prosthesis System", 
        "condition": "Retinitis Pigmentosa", 
        "condition_browse": {
            "mesh_term": [
                "Retinitis", 
                "Retinitis Pigmentosa"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Are adults, age 25 year or older;\n\n          -  Have severe to profound retinitis pigmentosa;\n\n          -  Bare light or no light perception in both eyes; if the patient has no residual light\n             perception, then evidence of intact inner layer retina function must be confirmed;\n\n          -  Have previous history of useful form vision.\n\n          -  Aphakic or pseudophakic.  (If the patient is phakic prior to implant, the natural\n             lens will be removed during the implant procedure.)\n\n          -  Patients who are willing and able to receive the recommended post-implant clinical\n             follow-up, device fitting, and visual rehabilitation;\n\n          -  Have consented to the implantation of an Argus II Retinal Prosthesis and subsequently\n             consent to participate in this study;\n\n          -  At the time of the Baseline Visit, do not suffer from non-ophthalmic serious adverse\n             events (e.g. myocardial infarction, etc.) and\n\n          -  Live no more than 3 hours distance from the Site where medical follow-up and device\n             fitting will be performed.\n\n        Exclusion Criteria:\n\n          -  Ocular diseases or conditions that could prevent Argus II System from working (e.g.\n             optic nerve disease, central retinal artery or vein occlusion, history of retinal\n             detachment, trauma, severe strabismus);\n\n          -  Ocular structures or conditions that could prevent the successful implantation of the\n             Argus II Implant or adequate healing from surgery (e.g. extremely thin conjunctiva,\n             axial length <20.5 mm or >26 mm, corneal ulcers, etc.);\n\n          -  Ocular diseases or conditions (other than cataracts) that prevent adequate\n             visualization of the inner structures of the eye (e.g. corneal opacity, etc.);\n\n          -  Inability to tolerate general anesthesia or the recommended antibiotic and steroid\n             regimen associated with the implantation surgery;\n\n          -  Metallic or active implantable device(s) (e.g. cochlear implant) in the head;\n\n          -  Pre-disposition to eye rubbing;\n\n          -  Any disease or condition that prevents understanding or communication of informed\n             consent, study demands, and testing protocols, including:\n\n               -  cognitive decline including diagnosed forms of dementia and/or progressive\n                  neurologic disease,\n\n               -  psychiatric disease including diagnosed forms of depression;\n\n               -  does not speak a principal language associated with the region, and\n\n               -  deafness;\n\n          -  Pregnant or wish to become pregnant during the course of the study;\n\n          -  Participating in another investigational drug or device study that may conflict with\n             the objectives, follow-up or testing of this study;\n\n          -  Conditions likely to limit life to less than 1 year from the time of inclusion."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "25 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Age 25 years or older; both males and females; with severe to profound retinitis\n        pigmentosa; with bare or no light perception in both eyes or with retinal response to\n        electrical stimulation; with previous history of useful form vision"
            }
        }, 
        "enrollment": {
            "#text": "53", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01860092", 
            "org_study_id": "PM-02"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 29, 2014", 
        "location": [
            {
                "contact": {
                    "email": "prosa@med.miami.edu", 
                    "last_name": "Potyra Rosa", 
                    "phone": "305-202-4731"
                }, 
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }, 
                    "name": "U. of Miami, Bascom Palmer Eye Institute"
                }, 
                "investigator": {
                    "last_name": "Byron Lam, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "oadeyem2@jhmi.edu", 
                    "last_name": "Olukemi Adeyemo", 
                    "phone": "443-287-0072"
                }, 
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }, 
                    "name": "Johns Hopkins, Lions Vision Center"
                }, 
                "investigator": {
                    "last_name": "Gislin Dagnelie, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "haag@med.umich.edu", 
                    "last_name": "Kari Branham", 
                    "phone": "734-936-8638"
                }, 
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48105"
                    }, 
                    "name": "University of Michigan, Kellogg Eye Center"
                }, 
                "investigator": {
                    "last_name": "Thiran Jayasundera, MD FACS", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "waelasky@umn.edu", 
                    "last_name": "Wendy Elasky", 
                    "phone": "612-626-3056"
                }, 
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55455"
                    }, 
                    "name": "University of Minnesota Department of Ophthalmology"
                }, 
                "investigator": {
                    "last_name": "Sandra Montezuma, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "latoya.greene@duke.edu", 
                    "last_name": "LaToya Greene", 
                    "phone": "919-684-9072"
                }, 
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke University Eye Center"
                }, 
                "investigator": {
                    "last_name": "Paul Hahn, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Hillary.Sedlacek@UHhospitals.org", 
                    "last_name": "Hillary Sedlacek", 
                    "phone": "216-844-7408"
                }, 
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44106"
                    }, 
                    "name": "University Hospitals Eye Institute"
                }, 
                "investigator": {
                    "last_name": "Suber Huang, MD, MBA", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "New Enrollment Post-Approval Study of the Argus\u00ae II Retinal Prosthesis System", 
        "overall_contact": {
            "email": "aripley@2-sight.com", 
            "last_name": "Anne-Marie Ripley", 
            "phone": "818-833-5034"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety (i.e. adverse event rates), with the main safety analysis performed when all subjects have reached 2 years post-implant.", 
            "safety_issue": "No", 
            "time_frame": "5 Years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01860092"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Visual function means how to the eye works (e.g. visual acuity). Visual function will be measured using the following test: Square Localization, Direction of Motion and Grating Visual Acuity (GVA).In addition to these tests, a photographic flash test will be performed with the System OFF only to determine if subjects' native residual vision is bare light perception or no light perception.", 
                "measure": "Visual function", 
                "safety_issue": "No", 
                "time_frame": "5 Years"
            }, 
            {
                "description": "Functional vision means how subjects perform in vision-related activities of daily living.  Function vision will be assessed using the Functional Low-Vision Observer Rated Assessment (FLORA).  A utilization questionnaire will also be administered to track how subjects are using the Argus II System.", 
                "measure": "Functional Vision", 
                "safety_issue": "No", 
                "time_frame": "5 Years"
            }, 
            {
                "description": "Device reliability will be measured by calculating the rate of implant failure over time.", 
                "measure": "Device Reliability", 
                "safety_issue": "No", 
                "time_frame": "5 Years"
            }
        ], 
        "source": "Second Sight Medical Products", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Second Sight Medical Products", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}